Cytoprotective Effects of Mesenchymal Stem Cells During Liver Transplantation from Donors After Cardiac Death in Rats

2018 ◽  
Vol 50 (9) ◽  
pp. 2815-2820 ◽  
Author(s):  
H. Sasajima ◽  
S. Miyagi ◽  
Y. Kakizaki ◽  
T. Kamei ◽  
M. Unno ◽  
...  
Keyword(s):  
Stem Cells ◽  
Liver Transplantation ◽  
Mesenchymal Stem Cells ◽  
Cardiac Death

Cytoprotective Effects of Mesenchymal Stem Cells During Liver Transplantation From Donors After Cardiac Death in Swine

2020 ◽  
Vol 52 (6) ◽  
pp. 1891-1900
Author(s):  
Hideaki Sasajima ◽  
Shigehito Miyagi ◽  
Shuhei Yamada ◽  
Yuta Kakizaki ◽  
Takashi Kamei ◽  
...  
Keyword(s):  
Stem Cells ◽  
Liver Transplantation ◽  
Mesenchymal Stem Cells ◽  
Cardiac Death

Impact of Ex Vivo Administration of Mesenchymal Stem Cells on the Function of Kidney Grafts From Cardiac Death Donors in Rat

2014 ◽  
Vol 46 (5) ◽  
pp. 1578-1584 ◽  
Author(s):  
S. Iwai ◽  
I. Sakonju ◽  
S. Okano ◽  
T. Teratani ◽  
N. Kasahara ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Cardiac Death ◽  
Ex Vivo

scholarly journals Research Status of Mesenchymal Stem Cells in Liver Transplantation

2019 ◽  
Vol 28 (12) ◽  
pp. 1490-1506 ◽  
Author(s):  
Yu You ◽  
Di-guang Wen ◽  
Jian-ping Gong ◽  
Zuo-jin Liu
Keyword(s):  
Stem Cells ◽  
Liver Transplantation ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
In Vivo Studies ◽  
Cell Contact ◽  
Clinical Effects ◽  
Clinical Safety

Liver transplantation has been deemed the best choice for end-stage liver disease patients but immune rejection after surgery is still a serious problem. Patients have to take immunosuppressive drugs for a long time after liver transplantation, and this often leads to many side effects. Mesenchymal stem cells (MSCs) gradually became of interest to researchers because of their powerful immunomodulatory effects. In the past, a large number of in vitro and in vivo studies have demonstrated the great potential of MSCs for participation in posttransplant immunomodulation. In addition, MSCs also have properties that may potentially benefit patients undergoing liver transplantation. This article aims to provide an overview of the current understanding of the immunomodulation achieved by the application of MSCs in liver transplantation, to discuss the problems that may be encountered when using MSCs in clinical practice, and to describe some of the underlying capabilities of MSCs in liver transplantation. Cell–cell contact, soluble molecules, and exosomes have been suggested to be critical approaches to MSCs’ immunoregulation in vitro; however, the exact mechanism, especially in vivo, is still unclear. In recent years, the clinical safety of MSCs has been proven by a series of clinical trials. The obstacles to the clinical application of MSCs are decreasing, but large sample clinical trials involving MSCs are still needed to further study their clinical effects.

scholarly journals Improvement of Liver Transplantation Outcome by Heme Oxygenase-1-Transduced Bone Marrow Mesenchymal Stem Cells in Rats

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Bin Wu ◽  
Hong-Li Song ◽  
Yang Yang ◽  
Ming-Li Yin ◽  
Bo-Ya Zhang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Liver Transplantation ◽  
Mesenchymal Stem Cells ◽  
Heme Oxygenase ◽  
Transforming Growth Factor ◽  
The Other ◽  
Heme Oxygenase 1 ◽  
Immunomodulatory Effects ◽  
Marrow Mesenchymal Stem Cells

Bone marrow mesenchymal stem cells (BMMSCs) exert immunosuppressive activity in transplantation, and heme oxygenase-1 (HO-1) enhances their immunomodulatory effects. The aim of this study was to determine whether HO-1-transduced BMMSCs (HO-1/MSCs) improve rat liver transplantation (LTx) outcomes. Orthotopic LTx rejection models were treated with HO-1/MSCs, BMMSCs, HO-1, or normal saline, respectively. Our results showed a significant improvement in survival rates in the HO-1/BMMSCs group compared to the control groups. At all time points, liver function marker levels in the HO-1/MSCs group were significantly lower than in the other three groups; on POD 1, 7, and 14, the degree of rejection and apoptotic cells was significantly less in the HO-1/MSCs group than in the other three groups. Interleukin- (IL-) 10 and transforming growth factor-βlevels were significantly increased, while IL-2, IL-6, IL-17, IL-23, tumor necrosis factor-α, and interferon-γlevels were significantly decreased in the HO-1/MSCs group when compared to the other groups. Splenocyte Tregs were significantly increased by HO-1/MSCs compared with controls on POD 3, 5, 7, 10, 14, and 28. Summarily, we provide evidence that HO-1/MSCs improved allogeneic LTx outcomes by attenuating inflammatory responses and acute cellular rejection, as well as enhanced immunomodulatory effects compared with BMMSCs.

Mesenchymal stem cells administered after liver transplantation prevent acute graft-versus-host disease in rats

2012 ◽  
Vol 18 (6) ◽  
pp. 696-706 ◽  
Author(s):  
Xuefeng Xia ◽  
Wei Chen ◽  
Tao Ma ◽  
Guodong Xu ◽  
Hao Liu ◽  
...  
Keyword(s):  
Stem Cells ◽  
Liver Transplantation ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft
Sign in / Sign up

Export Citation Format

Share Document